secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001493152-24-039586
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma enters consulting pact with Cross Current for $700K total compensation
--------------------------------------------------------------------------------

- Consulting agreement for $200,000 cash and restricted shares valued at $500,000, subject to a six-month true-up to maintain $500K value.
- Shares cannot exceed 9.99% of outstanding common stock; vest after six months with possible additional 'true up' shares.
- Services include investor marketing, M&A canvassing, capital markets advisory; term is 24 months starting from NYSE American listing.
- Compensation and agreement effective upon listing (Start Date); registration statement on Form S-8 planned within 30 days after listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224039586/0001493152-24-039586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224039586/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer